HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.

AuthorsHélène Monjanel, Laure Deville, Caroline Ram-Wolff, Marie-Dominique Venon, Patricia Franchi, Claire Benet, Eric de Kerviler, Marion Malphettes, Catherine Thieblemont, Pauline Brice
JournalBritish journal of haematology (Br J Haematol) Vol. 166 Issue 2 Pg. 306-8 (Jul 2014) ISSN: 1365-2141 [Electronic] England
PMID24673542 (Publication Type: Clinical Trial, Phase II, Letter)
Chemical References
  • Antineoplastic Agents
  • Immunoconjugates
  • Brentuximab Vedotin
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Brentuximab Vedotin
  • Hodgkin Disease (drug therapy)
  • Humans
  • Immunoconjugates (therapeutic use)
  • Lymphoma, Large-Cell, Anaplastic (drug therapy)
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: